Sempra (SRE) concluded trading on Wednesday at a closing price of $72.84, with 4.73 million shares of worth about $344.24 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.90% during that period and on April 03, 2025 the price saw a gain of about 1.79%. Currently the company’s common shares owned by public are about 651.46M shares, out of which, 651.00M shares are available for trading.
Stock saw a price change of 2.92% in past 5 days and over the past one month there was a price change of 3.13%. Year-to-date (YTD), SRE shares are showing a performance of -16.96% which increased to 2.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $64.89 but also hit the highest price of $95.77 during that period. The average intraday trading volume for Sempra shares is 5.51 million. The stock is currently trading 3.88% above its 20-day simple moving average (SMA20), while that difference is down -4.68% for SMA50 and it goes to -10.60% lower than SMA200.
Sempra (NYSE: SRE) currently have 651.46M outstanding shares and institutions hold larger chunk of about 91.28% of that.
The stock has a current market capitalization of $47.45B and its 3Y-monthly beta is at 0.65. PE ratio of stock for trailing 12 months is 16.49, while it has posted earnings per share of $4.42 in the same period. Its PEG reads 3.18 and has Quick Ratio of 0.49 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRE, volatility over the week remained 1.96% while standing at 2.40% over the month.
Stock’s fiscal year EPS is expected to drop by -2.16% while it is estimated to increase by 10.44% in next year. EPS is likely to grow at an annualized rate of 5.18% for next 5-years, compared to annual growth of 3.92% made by the stock over the past 5-years.
Coverage by Jefferies stated Sempra (SRE) stock as a Hold in their note to investors on March 03, 2025, suggesting a price target of $77 for the stock. On February 27, 2025, Barclays Downgrade their recommendations, while on February 26, 2025, UBS Downgrade their ratings for the stock with a price target of $78. Stock get a Neutral rating from Goldman on February 26, 2025.
